EUCTR2005-002805-21-SE进行中（未招募）不适用
A randomized, double-blind, placebo controlled, three-way crossover study exploring the efficacy of AZD3778 compared with placebo and an oral antihistamine (loratadine) in a model of seasonal allergic rhinitis - N/A
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •For inclusion in the study subjects must fulfil all of the following criteria:
- •1. Be willing and able to comply with study procedures and provide informed consent
- •2. Men and post-menopausal or surgically sterilised women aged 18 to 60 years inclusive, (women will be considered post-menopausal if they have been amenorrheic for 12 months and FSH plasma concentration is within the post
- •menopausal range as defined by the laboratory)
- •3. A clinical diagnosis of birch and/or timothy grass pollen induced seasonal allergic
- •rhinitis for at least the previous 2 years
- •4. The presence of allergic sensitivity to birch and /or timothy grass pollen verified by
- •a positive skin prick test documented within the previous 24 months or at Visit 1
- •5. Asymptomatic subjects out of season, as judged by the investigator
- •6. Subjects with need of treatment for their nasal symptoms during the pollen season
- •7. Reaction to a nasal allergen challenge resulting in at least five sneezes and/or
- •recorded score of = 2 on a scale from 0-3 in either of the symptoms nasal blockage
- •and/or runny nose
- •For inclusion in the genetic part of the study the subjects must fulfil the following criterion:
- •1. Provision of informed consent for genetic research
- •If a subject declines to participate in the genetic research, there will be no penalty or loss of benefit to the subject. The subject will not be excluded from other aspects of the study described in this Clinical Study Protocol, so long as they consent.
- •Are the trial subjects under 18?
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Any of the following is regarded as a criterion for exclusion from the study:
- •1. Any clinically relevant disease and /or abnormality which in the opinion of the
- •investigator, either put the subject at risk because of participation in the study or
- •influence the results of the study or the subjects ability to participate in the study.
- •2. Subjects with structural abnormalities of the nose or nasal disorder symptomatic
- •enough to cause significant nasal obstruction as judged by the investigator
- •3. Have a clinical diagnosis of asthma
- •4. Have perennial allergic or non-allergic rhinitis except for cat and dog sensitivity
- •under the condition that these subjects will not be exposed to cat and dogs during
- •the study period.
- •5. Any upper respiratory tract infection (bacterial, viral or fungal infections of the
- •airways) 2 weeks prior to Visit 1 being symptomatic enough to affect study
- •conduct or the well-being of the subject as judged by the investigator
- •6. Topical glucocorticosteroid treatment within 1 month prior to Visit 1
- •7. Systemic glucocorticosteroid therapy for any reason during 6 weeks prior to Visit 1
- •8. Antihistamine treatment within 1 week prior to Visit 1
- •9. Subjects on immunotherapy for seasonal allergies
- •10. BMI < 18 kg/m3 or body weight below 65 kg
- •11. A marked baseline prolongation of QT/QTc (eg repeated demonstration of a QTc
- •interval >450 ms for females and >430 ms for males
- •12. A history of additional risk factors for Torsade de pointes (eg heart failure,
- •hypokalemia, family history of Long QT syndrome)
- •13. The use of concomitant medications that prolong the QT/QTc interval.
- •14. Involvement in the planning and conduct of the study (applies to both AstraZeneca
- •staff or staff at the study site)
- •15. Participation in another clinical study within 1 month prior to Visit 1
- •16. Planned hospitalisation during the course of the study
- •17. Previous randomization in the present study
- •18. Past (within 1 year) or present alcohol or drug abuse
- •19. Suspected poor capability, as judged by the investigator, to follow instructions of the study
研究者
相似试验
已完成
Unknown
Bioavailability study in healthy volunteers.CTRI/2023/04/051789SPECNOVA
已完成
2 期
Bioavailability study on Healthy subjectsCTRI/2024/04/066483SPECNOVA LLC18
已完成
不适用
This is a randomized, double blind, placebo controlled, three group study in which the safety and efficacy of Curcuma caesia will be compared with Cyperus rotundus and Curcuma caesia for weight management in obese or overweight patients.CTRI/2016/01/006487Sami Labs Limited60
进行中（未招募）
1 期
A double-blind, randomised, placebo controlled, three-period crossover study to investigate the pharmacodynamic effect of two CRF-1 antagonists GSK561679 and GW876008 on meal induced cortisol responses in patients with IBS.Irritable Bowel SyndromeEUCTR2007-000929-22-IEGlaxoSmithKline R & D Limited
已完成
不适用
A randomized, double-blind, placebo controlled, four-period, cross-over study to evaluate the cognitive effects of single oral administration of roflumilast in aging-related memory impairmentmild memory impairmentsub-clinical cognitive deficitsmemory impairmentNL-OMON40236Takeda40